


 Cite this: *RSC Adv.*, 2023, **13**, 28773

Natural defense against multi-drug resistant *Pseudomonas aeruginosa*: *Cassia occidentalis* L. *in vitro* and *in silico* antibacterial activity†

 Raihan Rahman Imon,^a Md. Enamul Kabir Talukder,^a Shahina Akhter,^b Md. Saidul Islam,^c Foysal Ahammad,^d K. M. Anis-Ul-Haque,^f Md. Moniruzzaman,^g Mirola Afroze,^g Mala Khan,^g Mohammad Abu Hena Mostofa Jamal,^h Tanveer A. Wani,ⁱ Mohammad Jashim Uddin^{*j} and Md. Mashiar Rahman^{ID} ^{*a}

Cassia occidentalis L. is widely used in indigenous and traditional medicine, but its impact on multi-drug resistant (MDR) bacterial infections mostly remains unknown. Therefore, this study aimed to evaluate the *in vitro* antibacterial efficiency of methanol and ethyl acetate extracts of *C. occidentalis* L. leaves (MECOL and EAECOL) against multi-drug resistant *Pseudomonas aeruginosa* and to identify potential antibacterial agents through computational studies targeting the LasR protein. Initially, 82 compounds were identified using GC-MS analysis, and the functional groups were determined through FT-IR analysis. Both extracts of the plant exhibited dose-dependent antibacterial activity, with MICs of $104.16 \pm 36.08 \mu\text{g mL}^{-1}$ for MECOL and $83.33 \pm 36.08 \mu\text{g mL}^{-1}$ for EAECOL, and an MBC of $125 \mu\text{g mL}^{-1}$. Among the 82 compounds, 12 potential compounds were identified based on binding scores using molecular docking with the LasR protein and MM-GBSA analysis. Furthermore, screening for ADME properties, including physicochemical features, water solubility, lipophilicity, RO5 compliance, and toxicity, identified the top three compounds: methyl dihydrojasmonate, methyl benzoate, and 4a-methyl-4,4a,5,6,7,8-hexahydro-2(3H)-naphthalenone, which also demonstrated binding affinity with the active site residues of the LpxC protein of the bacteria. Additionally, molecular dynamics (MD) simulations confirmed the binding reliability of these three phytochemicals to LasR's active pocket, comparable to the protein native inhibitory ligands (C12-HSL). The study offers scientific support for the traditional use of *C. occidentalis* in treating bacterial infections, highlighting the potential of the three compounds as leads for developing LasR inhibitors to combat multi-drug resistant *P. aeruginosa*.

 Received 12th June 2023
 Accepted 11th September 2023

DOI: 10.1039/d3ra03923d

rsc.li/rsc-advances

Introduction

One of the significant biomedical challenges today is developing effective disease-modifying treatments for multidrug-resistant (MDR) bacteria. These MDR pathogens pose a persistent threat to public health and human well-being. Among them, *P. aeruginosa* infections are particularly concerning, as

they have developed resistance against current antibiotics by altering metabolic pathways for survival and persistence.¹ The bacteria are classified as a top priority by the World Health Organization for innovative therapeutic approaches, and it is a key concern, according to the U.S. Centers for Disease Control.² The bacteria cause infections with high mortality rates (up to 61%), posing significant challenges worldwide, especially

^aMolecular and Cellular Biology Laboratory, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore 7408, Bangladesh. E-mail: mm.rahman@just.edu.bd

^bDepartment of Biochemistry and Biotechnology, University of Science and Technology Chittagong, Foy's Lake, Chittagong 4202, Bangladesh

^cKorea Institute of Radiological & Medical Sciences, 75, Nowon-ro, Nowon-gu, Seoul, South Korea

^dLaboratory of Computational Biology, Biological Solution Centre (BioSol Centre), Jashore 7408, Bangladesh

^eDivision of Biological and Biomedical Sciences (BBS), College of Health & Life Sciences (CHLS), Hamad Bin Khalifa University (HBKU), Doha, Qatar

^fDepartment of Chemistry, Jashore University of Science and Technology, Jashore 7408, Bangladesh

^gBangladesh Reference Institute for Chemical Measurements (BRICM), Bangladesh Council of Scientific and Industrial Research, Dr Quadrat-i-Khuda Road, Dhanmondi, Dhaka 1205, Bangladesh

^hDepartment of Biotechnology and Genetic Engineering, Islamic University, Bangladesh

ⁱDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia

^jDepartment of Pharmacy, Jashore University of Science and Technology, Jashore 7408, Bangladesh

 † Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra03923d>


in intensive care and burn units.^{3,4} Nosocomial infections are a significant concern, occurring after hospitalization, and *P. aeruginosa* is known to colonize medical equipment, urinary catheters, and endotracheal tubes.⁵ The bacteria's infectivity, virulence, and pathogenicity, driven by Quorum Sensing (QS), allow it to function as a unified entity, making it challenging to eradicate even during antimicrobial treatment.^{6,7}

The QS systems are encoded by bacterial *lasR/lasI* and *rhlR/rhII* genes.⁸ The *lasI* gene encodes LasI, responsible for N-3-oxododecanoyl homoserine lactone (3OC12-HSL) synthesis, a QS signaling factor. Similarly, *rhlI* gene translates RhlI, which secretes N-butyl-L-homoserine lactone (C4-HSL), another QS influencer. These genes also code for the receptors LasR and RhlR, forming complexes that influence biofilm development, virulence, and pathogenicity.⁷⁻¹¹ Inhibiting the LasR receptor may prevent *P. aeruginosa*'s virulence and invasiveness, supported by the reduction of virulence in LasR mutants and the suppression of biofilm production by sitagliptin, a medication used for type 2 diabetes (T2D).¹²

P. aeruginosa's multidrug resistance is driving interest in alternative antimicrobial sources with minimal side effects. Natural plant products, with their diverse structures and multitarget functionality, show promise as potential antibacterial agents.^{13,14} Medicinal plants contain bioactive phytochemicals with clinical value, and bacteria do not easily develop resistance to them.^{15,16} For instance, plant-based antibacterial compounds like coumarins demonstrate high activity against *Staphylococcus aureus*.¹⁷ Berberine exhibits potent antibacterial activity against Gram-positive bacteria, including *Mycobacterium tuberculosis* and methicillin-resistant *Staphylococcus aureus*.¹⁸ Plumbagin acts as a growth inhibitor for *Escherichia coli*, *Enterobacter aerogenes*, and *Klebsiella pneumoniae*.¹⁹ *C. occidentalis* L., an ethnomedicinal herb, has been extensively used in traditional medicine for various ailments.²⁰ It exhibits antibacterial, antifungal, antioxidant, hepatoprotective, and other activities due to its rich phytochemical content.^{21,22}

The antibacterial activity of the plant *C. occidentalis* L. and its compounds against MDR bacteria remains undiscovered. Therefore, the study aims to explore the antibacterial potential and pharmacological properties of *C. occidentalis* L. phytochemicals, specifically targeting *P. aeruginosa*'s virulence and pathogenicity through biofilm formation. This comprehensive approach involves *in vitro* testing, *in silico* evaluation of pharmacokinetics, toxicity, and drug properties, as well as molecular dynamics simulations to validate lead compounds. The research findings are expected to contribute valuable insights into the potential therapeutic use of *C. occidentalis* L. leaves against *P. aeruginosa* and aid in the development of novel treatment strategies for MDR-related infections.

Materials and methods

Chemicals and reagents

Chemicals were sourced from various suppliers: Mayer's and Fehling's solutions obtained from Central Drug House (P) Ltd., pyridine (CAS: 110-86-1) and chloroform (CAS: 67-66-3) from Alfa Aesar, glacial acetic acid from PanReac AppliChem (CAS: 64-19-7),

and erythromycin antibiotic discs from Bio-Rad, USA. Additionally, NaCl, H₂O₂, NaOH from Wako Pure Chemicals Industries, Ltd., and nutrient broth and nutrient agar media from Liofilchem, Italy. Ethyl acetate (CAS: 141-78-6), methanol, HCl (CAS: 7647-01-0), CuSO₄ (CAS: 7758-99-8), H₂SO₄ (CAS: 7664-93-9), dimethyl sulfoxide (CAS: 67-68-5), ferric chloride (CAS: 10025-77-1), lead acetate (CAS: 6080-56-4), and sodium nitroprusside (CAS: 13755-38-9) were purchased from Merck, Darmstadt, Germany.

Plant collection

In January 2022, *C. occidentalis* L. leaves were collected from Churamonkathi, Jashore district, Bangladesh (latitude 23.2238° N, longitude 89.1646° W). The herb's authenticity was verified by Dr Sardar Nasiruddin, a taxonomist at the National Herbarium in Dhaka, Bangladesh. Collected leaves were washed, air-dried at room temperature (~25 °C), and ground into powder, then stored in an airtight container.²³

Plant extract preparation

Phytoextracts from *C. occidentalis* L. leaves were obtained following standard procedures described by Rahman *et al.* 2020.²³ The powdered plant material (100 g) was divided into two 1-liter conical flasks, one with 400 mL of methanol and the other with 400 mL of ethyl acetate. After 72 hours of shaking at 250 rotations per minute and 37 °C, the mixture was filtered using sterile cotton mesh and Whatman filter paper (number 1). The concentrated crude extracts were stored in sterilized tubes at 4 °C, yielding 5.5 g (dry weight, 5.5% w/w) of crude methanol extract and 5.77 g (dry weight, 5.77% w/w) of crude ethyl acetate extract from each 100 g of powdered plant material.

Qualitative phytochemical screening

Qualitative analysis of phytochemicals in MECOL and EAECOL solutions was conducted using previously methods describe by Rahman *et al.* 2023.²⁴ To detect phenolic compounds (flavonoids and tannins), alkaline reagents, FeCl₃, and Pb(OAc)₂ were employed. Alkaline reagent tests involved dropwise addition of MECOL and EAECOL solutions to NaOH (5%), followed by the addition of 10% HCl solution resulting in color disappearance. FeCl₃ (5%) solution was added to MECOL and EAECOL solutions (10 mg mL⁻¹), producing a reddish-black color.²⁵ For tannin detection, 10 mg of MECOL and EAECOL were mixed with chloroform, and 10% conc. Pb(OAc)₂ was added. The steroids test showed a dark-black color on the bottom surface. Mayer's test involved dissolving 25 mg of MECOL and EAECOL in 10 mL of aqueous HCl (1%) and adding Mayer's reagent. Legal tests were conducted to identify cardiac glycosides using pyridine, nitroprusside, and sodium hydroxide solution.²⁶ Fehling's assay was used to detect reducing sugars. Foaming and frothing assays were performed to test for the presence of saponin in MECOL and EAECOL solutions.

Gas chromatography-mass spectrometry (GC-MS) analysis

The GC-MS analysis followed a previously disclosed methodology described with slight modifications.²⁷ Shimadzu triple-



quad GCMS-TQ8040 was used to detect phytochemicals in MECOL and EAECOL. Helium gas was used as the mobile phase, and a Rtx-5MS capillary column (30 m 0.25 mm id, film thickness of 0.25 μm) was used as the stationary phase. The column oven temperature was adjusted using dedicated software. The sample injector temperature was maintained at 250 °C for a 40 minute run in splitless mode. The instrument settings included a continuous stream frequency of 1 mL min⁻¹, an interface temperature of 250 °C, an ion source temperature of 230 °C, a scanning range of 50–600 m/z , and an ionization energy of 70 eV with a scan period of 0.3 s. Phytochemicals were identified by contrasting retention time and spectral patterns, and matches were made to the National Institute of Standards and Technology database (NIST) for specific content (%) estimation in MECOL and EAECOL.

FT-IR spectroscopic analysis

FT-IR analysis of MECOL and EAECOL followed a previously established method by He *et al.*, (2020).²⁸ Phytoconstituents were loaded as KBr pellets in the FT-IR sample chamber, and the infrared spectra were obtained in the range of 4500 to 400 cm⁻¹ with a resolution of 4 cm⁻¹.

Bacterial strains collection

A glycerol stock of a multidrug-resistant *P. aeruginosa* bacterial strain (Gene Bank Accession Number: OK355439) was collected from the Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia, Bangladesh. This strain was isolated from medical center drainage water and tested for antibiotic susceptibility against various antibiotics, showing multiple antibiotic resistance.²⁹

Agar-well diffusion and disc diffusion assay

The antibacterial potential of MECOL and EAECOL was evaluated using agar-well diffusion and disc diffusion techniques against frozen MDR *P. aeruginosa* stock. Bacterial colonies were grown on LB agar and a confined colony of the bacteria was inoculated into 25 mL of LB broth and cultured for bacterial growth at 37 °C with constant agitation at 250 rpm, until the exponential phase of optical density (OD) reached 0.4 at 600 nm wavelength, as measured using a UV-spectrophotometer. Four wells were made in each LB agar Petri plate containing bacterial culture. Serial dilutions of MECOL and EAECOL (500 $\mu\text{g mL}^{-1}$) were added to wells. Erythromycin discs served as the standard and the discs of erythromycin in the center of the Petri plates were used as a negative control. Discs with various extract concentrations were placed on the agar plate. Blank discs with DMSO were used as a negative control. Zones of inhibition were measured after incubation at 37 °C for 16 hours, and the experiment was performed in triplicate.

MIC and MBC analysis

The MIC and MBC of MECOL and EAECOL were determined using a doubled serial dilution scheme. Stock solutions of MECOL and EAECOL (500 $\mu\text{g mL}^{-1}$) were diluted with LB broth

to concentrations of 250, 125, and 62.5 $\mu\text{g mL}^{-1}$. Bacterial samples were added to each tube and incubated at 37 °C for 24 hours. The lowest concentration preventing visible bacterial growth was identified as MIC. For MBC, cultures were sub-cultured on LB agar and incubated for 16 hours at 37 °C. The lowest concentration without visible bacterial growth on the agar plate was recorded as MBC. The experiments were conducted thrice for accuracy.

Retrieval and preparation of protein structure

The 3D X-ray crystallographic structures of the biofilm-forming LasR (PDB: 3IX3) and lipid A biosynthesis protein LpxC (PDB: 2ves) with their native ligands (C12-HSL and BB-78485, respectively) were obtained from the RCSB-PDB.^{6,30} The resolution of LasR and LpxC structures was determined to be 1.40 Å and 1.90 Å, respectively. Protein preparation was performed using the Schrodinger protein preparation wizard (version 2020-3), including bond order assignment, creation of zero-order bonds for metals, addition of disulfide bonds, and removal of water molecules.³¹ The protein structures were further refined, and energy minimized using the OPLS-3e force field.³²

Compounds preparation

In the GC-MS analysis, a total of 82 different phytochemicals were identified, with seven being identical in both MECOL and EAECOL extracts. The 3D structures of these phytochemicals were retrieved from the PubChem database and processed using the Ligprep wizard in the Maestro Schrodinger suite.³¹ High-energy ionization states of the ligand molecules were minimized at pH 7.0 using Epik version 5.3. The OPLS3e force field was applied to identify potential chiral centers and generate potential stereoisomers, followed by another minimization step.

Molecular docking

Natural phytochemicals identified through GS-MS were analyzed for protein–ligand binding scores using extra precision (XP) molecular docking with LasR. The Glide package in Glide v-8.8 and Maestro v-12.5.139 programs were utilized to assess the best binding scores between the phytochemicals and target proteins.^{33,34} Docking was performed in the standard precision mode with the OPLS3e force field. Binding positions of reference native inhibitor ligands, C12-HSL, and BB-78485-binding residues in LasR and LpxC active sites, respectively, were determined, and grid boxes were created accordingly. The center coordinates of the grid box were $X = 7.25, Y = 2.53, Z = 33.1, X = 9.55, Y = 3.83, Z = 29.1$ LasR and LpxC, respectively that determines the area where the ligand docking calculations were taken place. XP molecular docking simulations were conducted on the two proteins with 82 phytochemicals and native ligands, and from these simulations, target proteins and ligand-binding energy were extracted.

Molecular mechanics-generalized born surface area (MM-GBSA) analysis

In this study, a MM-GBSA analysis was conducted using the Prime MM-GBSA program package to estimate the binding-free



energy of ligands and validate the docking process between the LasR protein and ligands. The analysis considered negative MM-GBSA ΔG bind (NS), ΔG bind Coulomb (Coulomb energy), ΔG bind H-bond (hydrogen bond energy), ΔG bind lipo (lipophilicity energy), and ΔG bind vdW (van der Waals interaction energy) for the 12 highest-interacting ligands and the native ligand of the LasR protein.^{35,36} These features, representing energy contributions from different terms in the energy expression, provide valuable information on ligand, receptor, and complex structures, as well as energy differences related to strain and binding.

Pharmacokinetics (PK) and toxicity (T) analysis

In drug development, investigating absorption, distribution, metabolism, and excretion (ADME), properties including physicochemical properties, lipophilicity, water solubility, drug-likeness, and synthetic accessibility helps identify potential druggable compounds.⁹ We analyzed the top twelve phyto-ligand molecules with docking scores below five and MM-GBSA profile. To predict the PK properties, we used the SwissADME server (<https://www.swissadme.ch/>) with the SMILES format data of these molecules.³⁷ Additionally, we assessed toxicity using the ProTox-II web server (<https://toxnew.charite.de/>).³⁸

Molecular dynamics (MD) simulation

To assess protein–ligand interaction stability, a 100 ns MD simulation was conducted for the complex structures using “Desmond v6.3 Program” in Schrodinger 2020-3 on Linux. The simulation focused on LasR-phytochemical complex with a TIP3P water model. An orthorhombic box with 10 Å distance from the center maintained a specific volume, and Na⁺ and Cl⁻ ions were added to neutralize the system (0.15 M salt concentration). OPLS3e force field was applied.³⁹ The complex system was minimized under isothermal–isobaric (NPT) ensemble (pressure of 101325 pascals and temperature of 300 K). Stability and dynamic characteristics were analyzed using RMSD, RMSF, rGyr, and SASA values.

Statistical analysis

The antibacterial activity test results, performed at varying extract concentrations, were presented as the mean \pm standard

deviation (STD) of three independent replicates. The statistical analysis comprised one-way ANOVA conducted using Origin Lab 2018 software and Bonferroni's and Tukey's post hoc tests. Significance levels were indicated as * $p < 0.05$ and ** $p < 0.01$.

Results

Phytochemical screening

Phytochemical screening of *C. occidentalis* L. leaves revealed the presence of various compounds using standard color change methods listed in Table 1 and part of plant as well as primary phytochemical represented in Fig. S1 and S2.† Both MECOL and EAECOL showed light-yellow coloration with 5% NaOH, which faded to colorless with the addition of 10% HCl, indicating the presence of flavonoids.

Tannins were detected by the greenish-black coloration after treatment with 5% FeCl₃ and the formation of a grey-white precipitate with lead acetate. Terpenoids were confirmed by Salkowski's test, showing a light-yellow layer in the lower phase and a brown layer at the upper interface. Steroids were indicated by a deep brown layer in the lower phase and a light-yellow layer in the upper phase of Salkowski's test. Alkaloids were absent as Mayer's test did not produce creamy-white precipitation. Legal's test showed a blood-red color, confirming the presence of cardiac glycosides. Reducing sugars were detected with Fehling's test, resulting in a deep green and yellow-lime precipitation. Saponins were present, demonstrated by the 10 minute foaming stability in the foaming and frothing experiments.

FT-IR analysis

FT-IR analysis of MECOL and EAECOL detected various functional groups. Peaks in the spectrum indicated the presence of specific bonds and functional groups listed in Table 2 and shown in Fig. S3.† MECOL exhibited peaks at 3700–3000 cm⁻¹ and 1178.56, 2921.32, 2849.95, 1742.76, 1632.81, 1463.07–1383.96, and 418.57 cm⁻¹, indicating the presence of carboxylic acids, aliphatic hydrocarbons, aldehydes, aldehydes/esters, alkenes, alkanes, and alkyl halides.

EAECOL showed peaks at 3700–3000 cm⁻¹ and 1178.56, 2924.21, 2853.81, 1712.86, 1639.56, 1629.92, 1510.33, 1460.18, and 1384.95, 1401.34 and 839.07, 1071.50, 839.07, 721.41,

Table 1 Preliminary phytochemical screening of MECOL and EAECOL. The evaluation of phytochemicals from *C. occidentalis* L. leaves was performed using standard color change methods. “+” indicates the presence of a phytochemical, and “–” indicates its absence

Test name	Observation	MECOL	EAECOL	Phytochemical nature
Alkaline	Colorless solution	+	+	Phenolic (flavonoid)
Ferric chloride	Greenish-black coloration	+	+	Phenolic (tannins)
Lead acetate	Grey-white precipitation	+	+	Phenolic (tannins)
Salkowski's	Brown layer at upper interface	+	+	Terpenoids
Salkowski's	Blackish layer in the bottom face	+	+	Steroids
Mayer's	Creamy-colored precipitation absent	–	–	Absence of alkaloids
Legal's	Blood-red color	+	+	Cardiac glycosides
Foaming	Foam formation	+	+	Saponins
Fehling	Yellow-lime precipitation	+	+	Reducing sugar



Table 2 FT-IR spectral analysis of MECOL and EAECOL. The characteristic peak position in the spectrum usually corresponds to the vibrational mode of a particular bond

Extract	Wavelength (cm ⁻¹)	Peak intensity	Functional group
MECOL	3700–3000	Broad	Carboxylic acids (O–H stretch)
	2921.32	Weak	Aliphatic hydrocarbon (C–H stretch)
	2849.95	Weak	Aldehyde (C–H stretch)
	1742.76	Weak	Aldehyde or ester (C=O stretch)
	1632.81	Strong	Aromatic alkene (C=C stretch)
	1463.07	Weak	Alkane (–CH ₃ – bend)
	1383.96	Medium	Alkane (–CH ₃ – bend)
	418.57	Weak	Alkyl halide (C–X)
EAECOL	3700–3000	Broad	Carboxylic acids (O–H stretch)
	2924.21	Weak	Aliphatic hydrocarbon (C–H stretch)
	2853.81	Weak	Aldehyde (C–H stretch)
	1712.86	Medium	Aldehyde or ketone (C=O stretch)
	1639.56	Strong	Alkene (C=C stretch)
	1629.92	Strong	Primary or secondary amine (N–H bend)
	1510.33	Weak	Nitro (N=O stretch)
	1460.18	Medium	Alkane (–CH ₃ – bend)
	1401.34	Medium	Aldehyde/alkane (C–H bend)
	1384.95	Medium	Alkane (–CH ₃ – bend)
	1178.56	Weak	Carboxylic acids (C–O stretch)
	1071.5	Weak	Alcohol/phenol (O–H stretch)
	839.07	Weak	Aldehyde/alkane (C–H stretch)
	721.41	Weak	Alkyl halide (C–Cl)
	517.91	Weak	Alkyl halide (C–X)

517.91–419.57 cm⁻¹, indicating the presence of carboxylic acids, aliphatic hydrocarbons, aldehydes, aldehyde/ketone, alkene, primary or secondary amine, nitro, alkane, aldehyde/alkane, alcohol/phenol, alkyl chloride, and alkyl halide. A major peak at 1632 and 1639 cm⁻¹ indicated the presence of aromatic C=C bonds. The broad peak at 3700–3000 cm⁻¹ may arise from the hydroxyl group (O–H stretch) of carboxylic acids. A trace of carbonyl (C=O) bond for aldehydes and esters was found at around 1742 cm⁻¹ in methanol extract and 1712 cm⁻¹ in ethyl acetate extract.

GC-MS analysis of MECOL and EAECOL

MECOL and EAECOL exhibited 46 and 43 peaks respectively in their GC-MS chromatograms shown in Fig. 1(A) and (B). Each peak represented a distinct phytochemical, and we estimated their relative percentage amounts based on average peak areas compared to total areas with retention time (RT) provided in Tables S1 and S2.†

These peaks indicated the presence of specific phytochemicals with unique identities, dependent on their chemical formula, and structure. The phytochemical composition of MECOL consisted of alkane, alcohol, alkene, steroid, terpene, amide, ester, ether, ketone, tocopherols, and phenol, with the major compounds being stigmaterol, 13-docosenamide, neophytadiene, phytol, tetrapentacontane, 1-hexadecanol, and 9-octadecene (Table S1†). Similarly, the phytochemicals identified in EAECOL included esters, carbohydrates, carbonyl compounds, amide, terpenoids, alkane, steroids, alcohol, ketone, phenol, and alkyne, with the primary constituents being esters such as 6-octadecenoic acid and hexadecanoic acid, along with 3-O-methyl-D-glucose and 13-docosenamide (Table S2†). Notably, both

MECOL and EAECOL shared seven common phytochemicals (Table S3†) as identified through GC-MS analysis.

Antibacterial activity of *C. occidentalis* L. leaves extracts

In this study, we investigated the antibacterial potential of MECOL and EAECOL against multi-drug-resistant *P. aeruginosa*. The agar well diffusion and disc diffusion assays were conducted using various concentrations of MECOL and EAECOL (ranging from 62.55 to 500 µg mL⁻¹).

Our results demonstrated that both MECOL and EAECOL inhibited the proliferation of MDR *P. aeruginosa*, as evidenced by inhibition zones ranging from 9.33 ± 0.57 to 17.33 ± 0.57 mm for MECOL and 13.66 ± 0.57 to 17.66 ± 0.57 mm for EAECOL in the agar well diffusion assay represented in Fig. 2(A), (C) and (E). Similarly, in the disc diffusion assay, inhibition zones ranged from 7.33 ± 1 to 15.33 ± 0.57 mm for MECOL and 12 ± 1 to 16.66 ± 0.57 mm for EAECOL shown in Fig. 2(B), (D), and (F). Comparing the two compounds, EAECOL exhibited superior antimicrobial activity against *P. aeruginosa* in both the agar well diffusion and disc diffusion assays. Interestingly, erythromycin, a conventional antibiotic, showed no antibacterial activity against MDR *P. aeruginosa*, which had previously been confirmed to be resistant to erythromycin. The Minimum Inhibitory Concentration (MIC) values for MECOL and EAECOL were determined to be 104.16 ± 36.08 µg mL⁻¹ and 83.33 ± 36.08 µg mL⁻¹, respectively, while the Minimum Bactericidal Concentration (MBC) was found to be 125 µg mL⁻¹ for both compounds presented in Fig. S4.† However, to achieve complete bacterial eradication, a higher concentration of MECOL and EAECOL was required compared to the concentration that inhibited visible bacterial growth *in vitro*. The experiments were independently repeated three times, and






Fig. 1 GC-MS spectrometry of *C. occidentalis* L. leaves extracts, showing different peaks representing various compounds. (A) Chromatogram of MECOL and (B) chromatogram of the EAECOL.

the average values with standard deviations were presented. Statistical analyses indicated that EAECOL showed a significant difference from MECOL in agar well diffusion and disc diffusion assays ($*p < 0.05$, $**p < 0.01$). The standard antibiotic erythromycin discs further validated the results.

Molecular docking and MM-GBSA analysis

Our study performed molecular docking simulations and post-docking MM-GBSA analysis of 82 phytochemicals derived from

C. occidentalis L. leaves against the QS signaling molecule receptor, LasR, of *P. aeruginosa*. Out of the docked phytochemicals, 13 compounds displayed significant negative binding affinity, ranging from -5.417 to -8.01 kcal mol $^{-1}$, in comparison to the native LasR ligand, N-3-oxo-dodecanoyl-L-homoserine lactone (CID: 324694) having a binding score -5.375 kcal mol $^{-1}$ shown in Fig. 3A listed in Table S4.†

These 13 compounds were further subjected to MM-GBSA analysis and *in silico* investigations. Table S5† and Fig. 3B reveal that 12 phytochemical ligands exhibited favorable






Fig. 2 Antibacterial activity of MECOL and EAECOL against multi-drug resistant *P. aeruginosa*. Representing agar well diffusion assay and the inhibition zone exhibited by MECOL (A, E) and EAECOL (C, E) at different concentrations. Disc diffusion assay displays the inhibition zone produced by MECOL (B, F) and EAECOL (D, F).

binding free energy scores compared to the native ligand of LasR ($-13.9 \text{ kcal mol}^{-1}$), except CID 91716874, which showed a score of $-12.71 \text{ kcal mol}^{-1}$. Among these, CID 91716874 and CID 5365371 demonstrated the lowest and highest negative MM-GBSA ΔG binding (NS) scores of -12.71 and $-47.19 \text{ kcal mol}^{-1}$, respectively. The post-docking analysis of LasR–ligand complexes indicated various interaction energies, including ΔG bind Coulomb (Coulomb energy), ΔG bind H-bond (hydrogen bond energy), ΔG bind lipo (lipophilicity energy), and ΔG bind vdW (van der Waals interaction energy), contributing to the overall binding stability of the complexes. Overall, our findings suggest that the 12 identified compounds have a strong binding affinity compared to the native ligand of the LasR protein, indicating their potential as promising candidates for further exploration in inhibiting the QS signaling of *P. aeruginosa*.

Pharmacokinetics (ADME) and toxicity (T)

The ADME and toxicity assessment is vital for drug development, ensuring safety and efficacy for regulatory approval. Therefore, the ADME and toxicity of the 12 compounds have been identified.

Human intestinal absorption (HIA) is essential for drug bioavailability, with seven compounds showing high HIA and 5 exhibiting low HIA. BBB permeability was observed in 7 compounds, indicating CNS targeting, while five compounds lacked this potential. All 12 compounds were non-inhibitors of CYP450 enzymes, ensuring reduced metabolism interference. Nine compounds showed moderate clearance for drug excretion, while 3 had high clearance tendencies. In terms of toxicity, the 12 compounds showed promising results *in silico* evaluations, being non-hepatotoxic, non-carcinogenic, non-mutagenic, non-immunogenic, and non-cytotoxic. Seven compounds were non-toxic according to EPA toxicity categories, while five were toxic and listed in Table S6.† The physicochemical properties of the 12 compounds were assessed for their ADME influence. All compounds displayed favorable molecular weight, hydrogen bond acceptors (HBA), hydrogen bond donors (HBD), heavy atoms, and topological polar surface area (TPSA) for absorption. Additionally, they had appropriate rotatable bond (RB) counts, indicating good absorption listed in Table S7.† Molecules with cLogP values of ≤ 5 are considered to have strong absorption, and nine compounds met this criterion. Three compounds were predicted to cross the






Fig. 3 Molecular docking and MM-GBSA of phytochemicals derived from *C. occidentalis* L. against LasR. (A) Docking-based binding energy of the top 13 phytochemicals derived from *C. occidentalis* L. The binding energy values were obtained through molecular docking simulations, which predict the strength of interaction between the phytochemicals and the LasR protein. (B) Post-docking analysis of MM-GBSA ΔG binding (NS) scores of the compounds with LasR protein. The MM-GBSA method was applied to assess further the binding affinities of the phytochemicals identified in the docking study. Lower MM-GBSA ΔG binding (NS) scores indicate stronger binding interactions between the compounds and the LasR protein.

membrane bilayer based on acceptable LogS values. Five compounds satisfied Lipinski's rule of five for drug-likeness, and eleven compounds showed ease of synthesis. Among these compounds, methyl dihydrojasmonate, methyl benzoate, and 4a-methyl-4,4a,5,6,7,8-hexahydro-2(3H)-naphthalenone were identified as the best-hit compounds based on their favorable pharmacokinetics, lack of toxicity, and suitable drug-ability profiles.

Protein–ligands interactions

Various non-bonded interactions, such as hydrogen bonds, hydrophobic bonds, and electrostatic bonds, were observed between LasR and the best-hit phytochemicals. Methyl dihydrojasmonate displayed a hydrogen bond with TYR 56 and ASP 73, alongside other interactions, resulting in a binding affinity of -5.923 kcal mol⁻¹. Methyl benzoate showed a hydrogen bond with TYR 56 and SER 129, and other interactions, with a binding affinity of -5.811 kcal mol⁻¹. 4a-Methyl-4,4a,5,6,7,8-hexahydro-2(3H)-naphthalenone had a binding affinity of -5.472 kcal mol⁻¹ with LasR, without a hydrogen bond but containing various other interactions. In contrast, the LasR-native ligand complex formed with a binding energy of -5.375 kcal mol⁻¹, featuring a single TRP 60 hydrogen bond and other interactions. Fig. 4 illustrates the 3D and 2D interactions between the designated three phytochemicals (CID: 7150, CID: 136654, CID: 102861) and LasR, along with the LasR native ligand (CID: 3246941), within the protein's active pocket. The molecular docking interactions and interacting residues of LasR quorum sensing protein with the best phytochemical compounds and the native ligand are listed for each docked complex in Table S7.†

Multi-targeting capabilities analysis of the phytochemicals

To explore the inhibitory potential and multi-targeting capabilities of the lead phytochemicals from *C. occidentalis*, we conducted molecular docking simulations with the LpxC

enzyme. LpxC plays a crucial role in the synthesis of toxic bacterial outer lipid A membrane in Gram-negative *P. aeruginosa* and is a key target for antibiotic development. The phytochemicals CID 102861, CID 136654, and CID 7150 exhibited interactions with the LpxC target protein, with binding energies of -4.772 , -4.488 , and -3.505 kcal mol⁻¹, respectively. In comparison, the native inhibitor of LpxC, CID 9823454, formed a bond with a binding energy of -4.604 kcal mol⁻¹. This suggests that the potential lead phytochemicals have additional inhibitory interactions with the LpxC enzyme involved in lipid A biosynthesis, as shown in Table S9.†

MD simulation

To assess the stability of the three potential hit phytochemicals (CID7150, CID102861, and CID136654) within the protein's binding site, MD simulations of the protein–ligand complex structure were conducted. The analysis considered parameters such as Root Mean Square Deviation (RMSD), Root Mean Square Fluctuation (RMSF), Radius of Gyration (Rg), and Solvent Accessible Surface Area (SASA) to evaluate the constancy of the interactions between the LasR protein and the selected phytochemicals.

RMSD analysis

During the 100 ns simulation, the RMSD of C α atoms was measured to evaluate the stability of the protein–ligand complex structure. Fig. 5A illustrates the average fluctuation of the selected phytochemicals (CID 7150, CID 102861, and CID 136654), which showed values of 1.45 Å, 1.47 Å, and 1.62 Å, respectively. The LasR apoprotein and native ligand complex exhibited average fluctuations of 1.42 Å and 1.65 Å, respectively. These minimal fluctuations, falling well within the acceptable range of 1–3 Å, indicate the conformational stability of the protein–ligand complex structure. Throughout the simulation trajectory, the compounds remained stable, with only minor






Fig. 4 Depicts the molecular interactions between the *P. aeruginosa* LasR protein and three specific phytocompounds, as illustrated in both 3D (left) and 2D (right) representations. The compounds are as follows: (A) CID: 7150, (B) CID: 136654, (C) CID: 102861, additionally, (D) represents the LasR protein with native complex ligands CID: 3246941. The interactions are visualized within the active pocket of the LasR protein.

fluctuations, affirming their structural stability. The highest RMSD fluctuation for CID 7150, CID 102861, and CID 136654 was 1.86 Å, 1.94 Å, and 2.01 Å, respectively, while the lowest RMSD value range was 0.98 Å, 0.87 Å, and 0.939 Å. Similarly, for the apoprotein and the native ligand (CID 3246941), the range was 0.93 Å to 2.40 Å and 0.84 Å to 2.18 Å, indicating good stability, resembling the apoprotein and native compounds as promising lead antibacterial agents.

RMSF analysis

To assess the flexibility of the LasR protein in response to specific ligand interactions, RMSF values of compounds CID 7150, CID 102861, and CID 136654 were analyzed (Fig. 5B). The LasR apo protein showed peak fluctuations at HIS 169, GLU 168, ASP 43, PHE 167, and LYS 42 residues, while the native ligand exhibited fluctuations at HIS 169, HIS 169, GLU 168, PHE 7, and GLU 168 residues. The three selected compounds shared a common peak area at the HIS 169-residue location, indicating significant alterations during the simulation. CID 3246941 (native ligand) exhibited a higher RMSF value of 5.308 at residue 162, along with the apoprotein. For CID 7150, CID 102861, and CID 136654, RMSF values were 3.467, 2.368, 3.551, and 4.623, respectively, with CID 7150 showing the highest rigidity.

Radius of gyration (Rg)

The radius of gyration (Rg) was analyzed to assess the distribution of atoms around the axis of the protein–compound

complexes. CID 102861, CID-7150, CID-136654, and the native ligand (CID 3246941) stability in complex with the LasR protein were examined based on their Rg values over 100 ns simulations (Fig. 5C). The CID 3246941 (native ligand) and CID 102861 showed Rg ranges of 5.265 Å to 4.431 Å (fluctuation of 0.834 Å) and 3.755 Å to 3.097 Å (fluctuation of 0.658 Å), respectively. On the other hand, CID 7150 and CID 136654 exhibited Rg ranges of 2.395 Å to 2.263 Å (fluctuation of 0.132 Å) and 2.441 Å to 2.333 Å (fluctuation of 0.108 Å). Notably, all three phytocompounds demonstrated greater stability in 100 ns simulations, with lower fluctuation ranges compared to native ligand complexes, suggesting minimal conformational changes in the LasR active site due to the binding of the selected phytocompounds.

Solvent accessible surface area (SASA)

SASA analysis was performed for the specific phytocompounds to determine the solvent-like characteristics (hydrophobic or hydrophilic) of the LasR protein and protein–compound complexes (Fig. 5D). The native ligand of LasR exhibited a fluctuation range from 0.015 Å² to 14.608 Å², with an average fluctuation of 3.287 Å². In contrast, phytocompounds CID 7150, CID 102861, and CID 136654 showed fluctuation ranges of 0.121 Å² to 28.514 Å², 0.004 Å² to 18.845 Å², and 0.073 Å² to 30.044 Å², respectively, with average fluctuations of 14.14 Å², 4.74 Å², and 12.36 Å². These values indicate the exposure of amino acid residues to the designated phytocompounds in complex systems, suggesting distinct hydrophobic or hydrophilic interactions.




Fig. 5 Molecular dynamics simulation of representative ligand and protein complexes calculated from a 100 ns simulation. (A) RMSD values extracted from $C\alpha$ atoms of the protein–ligand docked complex. LasR protein as apoprotein and native ligand shown in gray and gold, respectively, while the selected compounds CID 7150, CID 102861, and CID 136654 represented by red, green, and orange, respectively. (B) RMSF values extracted from protein $C\alpha$ atoms of the docked protein–ligand complex. LasR apoprotein depicted in light blue, native ligand CID 3246941 in dark blue, and the designated compounds CID 7150, CID 102861 and CID 136654 in complex with LasR in orange, gray, and gold, respectively. (C) Radius of gyration (Rg) of the protein–ligand complexes. Rg values of CID 7150, CID 102861, CID 136654, and native ligand (CID 3246941) in complex with LasR represented by blue, orange, gray, and gold, respectively. (D) Graphic representation of the protein–ligand complex's solvent accessible surface area (SASA). SASA values of CID 7150, CID 102861, CID 136654, and native ligand (CID 3246941) in complex with LasR denoted by blue, orange, gray, and gold, respectively.

Discussion

P. aeruginosa poses a significant threat to public health, especially in hospitals and intensive care units, due to its multidrug-resistant nature.³⁹ Current treatment strategies rely on a combination of antibiotics, but the emergence of resistance and associated side effects has led to a pressing need for innovative antibacterial medications.^{40,41} In this context, there is growing interest in exploring phytochemicals as potential antimicrobial agents, as they offer diverse chemical structures and biological activities with minimal side effects.

Our study focused on the antibacterial potential of *C. occidentalis* leaf extracts and their phytochemicals against MDR *P. aeruginosa*. Prior research has explored the antimicrobial activity of these leaf extracts against various pathogens, but there was a lack of information on their activity against MDR *P. aeruginosa*. Therefore, we aimed to investigate the antibacterial properties of these phytochemicals, particularly targeting LasR, a crucial factor involved in drug resistance.

Initially, GC-MS analysis identified 82 chemical structures, which were docked and analyzed for MM-GBSA to assess their potential as antibacterial agents targeting LasR. Molecular docking simulation identified 13 lead phytochemicals with higher binding affinity, whereas MM-GBSA identified 12 best compounds binding to LasR and evaluated their pharmacokinetics, toxicity, and drug-ability profiles. CID 7150, CID 102861,

and CID 136654 showed the most promising characteristics and were selected for further studies. We also evaluated the interaction of these phytochemicals with LpxC, an enzyme involved in lipid A biosynthesis, which is crucial for bacterial outer membrane synthesis.⁴² The lead phytochemicals demonstrated multitargeting ability and drug-like properties, making them attractive candidates for antimicrobial therapeutics.

Molecular dynamics simulations were performed to assess the stability and structural changes of the protein–ligand complexes. The RMSD, RMSF, Rg, and SASA analyses revealed that the selected phytochemicals formed stable complexes with LasR, indicating their potential as antibacterial agents against MDR *P. aeruginosa*.

Among the lead phytochemicals, methyl dihydrojasmonate (CID 102861) has been reported for its diverse activities, including anticancer⁴³ and antimicrobial properties.⁴⁴ Methyl benzoate (CID 7150) has shown promise as an environmentally friendly insecticide⁴⁵ and an antibacterial agent⁴⁶ against Gram-negative bacteria. Considering the diverse parameters used for evaluation, CID 7150, CID 102861, and CID 136654 were identified as the most promising lead phytochemicals for developing antibacterial drugs against MDR *P. aeruginosa* and related infectious diseases. These compounds warrant further investigation in human *in vivo* studies to validate their potential as antimicrobial therapeutics.



Conclusion

In this study, *C. occidentalis* L. extract exhibited antibacterial activity against MDR *P. aeruginosa*, as demonstrated by inhibitory zones in disc diffusion and agar well diffusion tests. Computer-aided drug design identified three lead compounds (methyl dihydrojasmonate, methyl benzoate, and 4a-methyl-4,4a,5,6,7,8-hexahydro-2(3*H*)-naphthalene) that competitively inhibited LasR, the key signaling molecule receptor responsible for *P. aeruginosa*'s virulence and multi-drug resistance. These findings offer potential for developing new bioactive compounds to combat antibiotic-resistant infections. Further *in vivo* evaluations are needed to validate our results.

Author contributions

Raihan Rahman Imon: writing – original draft, investigation, methodology, formal analysis. EKT: investigation, methodology, formal analysis. Shahina Akhter: conceptualization, supervision, writing – review & editing. MSI: resources, writing – review & editing. Foysal Ahammad: resources; software; writing – review & editing; visualization. K. M. Anis-Ul-Haque: writing – review & editing; formal analysis. Md. Moniruzzaman: formal analysis; methodology. Mirola Afroze: formal analysis; methodology. Mala Khan: resources, data curation, validation. Mohammad Abu Hena Mostofa Jamal: resources. Tanveer A. Wani: funding acquisition, writing – review & editing. Mohammad Jashim Uddin: conceptualization, funding acquisition, writing – review & editing. Md. Mashiar Rahman: conceptualization, resources, Supervision, project administration, funding acquisition, writing – review & editing.

Conflicts of interest

The authors affirm that they have no known competing financial interests or personal relationships that could have influenced the work presented in this paper.

Acknowledgements

This research was supported by the Research Cell of Jashore University of Science and Technology, Bangladesh (grant ID: JUST/Research Cell/22-FoBST-06/2022-2023). The authors extend their appreciation to researchers supporting project number (RSP2023R357) at King Saud University, Riyadh, Saudi Arabia, for funding this research.

References

- 1 J. P. Horcajada, M. Montero, A. Oliver, *et al.*, Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections, *Clin. Microbiol. Rev.*, 2019, **32**, e000311–e000319.
- 2 E. Tacconelli, E. Carrara, A. Savoldi, *et al.*, Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis, *Lancet Infect. Dis.*, 2018, **18**, 318–327.
- 3 L. Raka, S. Kalenc, Z. Bosnjak, *et al.*, Molecular epidemiology of *Acinetobacter baumannii* in central intensive care unit in Kosova teaching hospital, *Braz. J. Infect. Dis.*, 2009, **13**, 408–413.
- 4 H. Fazzeli, R. Akbari, S. Moghim, *et al.*, *Pseudomonas aeruginosa* infections in patients, hospital means, and personnel's specimens, *J. Res. Med. Sci.*, 2012, **17**, 332–337.
- 5 J. A. Driscoll, S. L. Brody and M. H. Kollef, The epidemiology, pathogenesis and treatment of *Pseudomonas aeruginosa* infections, *Drugs*, 2007, **67**, 351–368.
- 6 I. Mochalkin, J. D. Knafels and S. Lightle, Crystal structure of LpxC from *Pseudomonas aeruginosa* complexed with the potent BB-78485 inhibitor, *Protein Sci.*, 2008, **17**, 450–457.
- 7 M. Kostylev, D. Y. Kim, N. E. Smalley, *et al.*, Evolution of the *Pseudomonas aeruginosa* quorum-sensing hierarchy, *Proc. Natl. Acad. Sci. U.S.A.*, 2019, **116**, 7027–7032.
- 8 G. Rampioni, I. Bertani, E. Zennaro, *et al.*, The quorum-sensing negative regulator RsaL of *Pseudomonas aeruginosa* binds to the *lasI* promoter, *J. Bacteriol.*, 2006, **188**, 815–819.
- 9 W. Zhou, Y. Wang, A. Lu, *et al.*, Systems pharmacology in small molecular drug discovery, *Int. J. Mol. Sci.*, 2016, **17**, 246.
- 10 S. Mukherjee, D. Moustafa, C. D. Smith, *et al.*, The RhlR quorum-sensing receptor controls *Pseudomonas aeruginosa* pathogenesis and biofilm development independently of its canonical homoserine lactone autoinducer, *PLoS Pathog.*, 2017, **13**, e1006504.
- 11 G. Krishnamoorthy, I. V. Leus, J. W. Weeks, *et al.*, Synergy between active efflux and outer membrane diffusion defines rules of antibiotic permeation into Gram-negative bacteria, *mBio*, 2017, **8**, e01172.
- 12 H. A. Abbas, M. A. Shaldam and D. Eldamasi, Curtailing quorum sensing in *Pseudomonas aeruginosa* by sitagliptin, *Curr. Microbiol.*, 2020, **77**, 1051–1060.
- 13 E. M. Abdallah, Plants: an alternative source for antimicrobials, *J. Appl. Pharm. Sci.*, 2011, **1**, 16–20.
- 14 U. Anand, N. Jacobo-Herrera, A. Altemimi, *et al.*, A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery, *Metabolites*, 2019, **9**, 258.
- 15 E. Patridge, P. Gareiss, M. S. Kinch, *et al.*, An analysis of FDA-approved drugs: natural products and their derivatives, *Drug Discovery Today*, 2016, **21**, 204–207.
- 16 K. Keita, C. Darkoh and F. Okafor, Secondary plant metabolites as potent drug candidates against antimicrobial-resistant pathogens, *SN Appl. Sci.*, 2022, **4**, 209.
- 17 K. Lewis and F. M. Ausubel, Prospects for plant-derived antibacterials, *Nat. Biotechnol.*, 2006, **24**, 1504–1507.
- 18 M. Tillhon, L. M. G. Ortiz, P. Lombardi, *et al.*, Berberine: new perspectives for old remedies, *Biochem. Pharmacol.*, 2012, **84**, 1260–1267.
- 19 D. Żaluski, L. Ciesla, Z. Janeczko, *et al.*, The structure-activity relationships of plant secondary metabolites with antimicrobial, free radical scavenging and inhibitory activity toward selected enzymes, *Stud. Nat. Prod. Chem.*, 2015, **45**, 217–249.



- 20 J. P. Yadav, V. Arya, S. Yadav, *et al.*, *Cassia occidentalis* L., A review on its ethnobotany, phytochemical and pharmacological profile, *Fitoterapia*, 2010, **81**, 223–230.
- 21 M. Bhagat, A. K. Saxena, *et al.*, Evaluation of *Cassia occidentalis* for *in vitro* cytotoxicity against human cancer cell lines and antibacterial activity, *Indian J. Pharmacol.*, 2010, **42**, 234–237.
- 22 Rajni, S. S. Gautam and Navneet, Antibacterial and phytochemical analysis of *Cassia occidentalis* L. seeds against respiratory tract pathogens, *Indian J. Nat. Prod. Resour.*, 2014, **5**, 52–55.
- 23 M. M. Rahman, M. M. Kabir, M. A. A. Noman, *et al.*, *Mikania cordata* leaves extract promotes activity against pathogenic bacteria and anticancer activity in EAC cell-bearing swiss albino mice, *J. Appl. Pharm. Sci.*, 2020, **10**, 112–122.
- 24 M. M. Rahman, M. A. A. Noman, S. Khatun, *et al.*, Evaluation of *Senna tora* (L.) Roxb. leaves as source of bioactive molecules with antioxidant, anti-inflammatory and antibacterial potential, *Heliyon*, 2023, **9**, e12855.
- 25 M. A. Aziz, *et al.*, Qualitative phytochemical screening and evaluation of anti-inflammatory, analgesic and antipyretic activities of *Microcos paniculata* barks and fruits, *J. Integr. Med.*, 2015, **13**, 173–184.
- 26 S. Akhter, M. W. Hossain, S. Sultana, *et al.*, *Ruellia prostrata* Poir. activity evaluated by phytoconstituents, antioxidant, anti-inflammatory, antibacterial activity, and *in silico* molecular functions, *J. Saudi Chem. Soc.*, 2022, **26**, 101401.
- 27 R. Alam, R. R. Imon, M. E. K. Talukder, *et al.*, GC-MS analysis of phytoconstituents from *Ruellia prostrata* and *Senna tora* and identification of potential anti-viral activity against SARS-CoV-2, *RSC Adv.*, 2021, **11**, 40120–40135.
- 28 Y. He, Y. Jia, F. Lu, *et al.*, New products generated from the transformations of ferulic acid dilactone, *Biomolecules*, 2020, **10**, 175.
- 29 M. A. H. M. Jamal, M. A. A. Mashud, M. Moinuzzaman, *et al.*, Green synthesis of silver nanoparticles using *Cinnamomum tamala* (Tejpata) leaf and their potential application to control multidrug resistant *Pseudomonas aeruginosa* isolated from hospital drainage water, *Heliyon*, 2022, **8**, e09920.
- 30 P. W. Rose, A. Prlic, A. Altunkaya, *et al.*, The RCSB protein data bank: integrative view of protein, gene and 3D structural information, *Nucleic Acids Res.*, 2017, **45**, D271–D281.
- 31 G. M. Sastry, M. Adzhigirey, T. Day, *et al.*, Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments, *J. Comput.-Aided Mol. Des.*, 2013, **27**, 221–234.
- 32 E. Harder, W. Damm, J. Maple, *et al.*, OPLS3: a force field providing broad coverage of drug-like small molecules and proteins, *J. Chem. Theory Comput.*, 2016, **12**, 281–296.
- 33 R. A. Friesner, R. B. Murphy, M. P. Repasky, *et al.*, Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes, *J. Med. Chem.*, 2006, **49**, 6177–6196.
- 34 D. Shivakumar, E. Harder, W. Damm, *et al.*, Improving the prediction of absolute solvation free energies using the next generation OPLS force field, *J. Chem. Theory Comput.*, 2012, **8**, 2553–2558.
- 35 P. D. Lyne, M. L. Lamb, J. C. Saeh, *et al.*, Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring, *J. Med. Chem.*, 2006, **49**, 4805–4808.
- 36 F. Ahammad, R. Alam, R. Mahmud, *et al.*, Pharmacoinformatics and molecular dynamics simulation-based phytochemical screening of neem plant (*Azadirachta indica*) against human cancer by targeting MCM7 protein, *Briefings Bioinf.*, 2021, **22**, bbab098.
- 37 B. G. Gimenez, M. S. Santos, M. Ferrarini, *et al.*, Evaluation of blockbuster drugs under the rule-of-five, *Pharmazie*, 2010, **65**, 148–152.
- 38 P. Banerjee, A. O. Eckert, A. K. Schrey, *et al.*, ProTox-II: a webserver for the prediction of toxicity of chemicals, *Nucleic Acids Res.*, 2018, **46**, W257–W263.
- 39 P. Pachori, R. Gothwal and P. Gandhi, Emergence of antibiotic resistance *Pseudomonas aeruginosa* in intensive care unit; a critical review, *Genes Dis.*, 2019, **6**, 109–119.
- 40 D. C. Nwobodo, M. C. Ugwu, C. O. Anie, *et al.*, Antibiotic resistance: the challenges and some emerging strategies for tackling a global menace, *J. Clin. Lab. Anal.*, 2022, **36**, e24655.
- 41 J. Murugaiyan, P. A. Kumar, G. S. Rao, *et al.*, Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics, *Antibiotics*, 2022, **11**, 200.
- 42 E. M. Fivenson and T. G. Bernhardt, An essential membrane protein modulates the proteolysis of LpxC to control lipopolysaccharide synthesis in *Escherichia coli*, *mBio*, 2020, **11**, e00939.
- 43 R. Yehia, R. M. Hathout, D. A. Attia, *et al.*, Anti-tumor efficacy of an integrated methyl dihydrojasmonate transdermal microemulsion system targeting breast cancer cells: *in vitro* and *in vivo* studies, *Colloids Surf., B*, 2017, **155**, 512–521.
- 44 F. Yildirim, Y. Memis, A. Ozturk, *et al.*, Antimicrobial activity of the essential oil and the extracts of *Kitaibelia balansae* species, *J. Essent. Oil Bear. Plants*, 2017, **20**, 809–819.
- 45 M. M. Mostafiz, E. Hassan, K.-Y. Lee, *et al.*, Methyl benzoate as a promising, environmentally safe insecticide: current status and future perspectives, *Agriculture*, 2022, **12**, 378.
- 46 S. Mohanapriya, M. Muthukumaran and S. Vairam, Synthesis, characterization, thermal behavior and antimicrobial activity of 3-methyl benzoate complexes of transition metal with hydrazine, *Bull. Chem. Soc. Ethiop.*, 2016, **30**, 241–252.

